Equities research analysts predict that Portola Pharmaceuticals Inc (NASDAQ:PTLA) will announce ($0.84) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Portola Pharmaceuticals’ earnings, with estimates ranging from ($0.92) to ($0.66). Portola Pharmaceuticals posted earnings of ($1.08) per share in the same quarter last year, which indicates a positive year over year growth rate of 22.2%. The business is scheduled to issue its next quarterly earnings report on Wednesday, November 6th.
On average, analysts expect that Portola Pharmaceuticals will report full year earnings of ($3.83) per share for the current financial year, with EPS estimates ranging from ($3.95) to ($3.70). For the next financial year, analysts expect that the business will post earnings of ($2.37) per share, with EPS estimates ranging from ($2.73) to ($1.68). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Portola Pharmaceuticals.
Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.13. The firm had revenue of $28.42 million during the quarter, compared to analysts’ expectations of $25.42 million. Portola Pharmaceuticals had a negative net margin of 379.94% and a negative return on equity of 352.12%. The firm’s revenue for the quarter was up 608.7% on a year-over-year basis. During the same period in the prior year, the company posted ($1.61) earnings per share.
NASDAQ PTLA traded up $0.22 during trading hours on Friday, hitting $30.68. 1,144,660 shares of the stock were exchanged, compared to its average volume of 962,989. The company has a market cap of $2.08 billion, a price-to-earnings ratio of -6.12 and a beta of 2.13. Portola Pharmaceuticals has a 12-month low of $14.81 and a 12-month high of $37.95. The stock has a 50-day moving average of $28.39 and a 200 day moving average of $30.25. The company has a quick ratio of 3.61, a current ratio of 3.63 and a debt-to-equity ratio of 453.47.
In other Portola Pharmaceuticals news, Director Hollings Renton sold 5,000 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $30.00, for a total transaction of $150,000.00. Following the transaction, the director now directly owns 18,194 shares in the company, valued at $545,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.50% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in PTLA. Geode Capital Management LLC grew its position in shares of Portola Pharmaceuticals by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 730,249 shares of the biopharmaceutical company’s stock valued at $14,254,000 after purchasing an additional 33,734 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Portola Pharmaceuticals in the first quarter valued at approximately $438,000. BNP Paribas Arbitrage SA grew its position in shares of Portola Pharmaceuticals by 355.2% in the first quarter. BNP Paribas Arbitrage SA now owns 15,040 shares of the biopharmaceutical company’s stock valued at $522,000 after purchasing an additional 11,736 shares during the last quarter. Bank of Montreal Can grew its position in shares of Portola Pharmaceuticals by 50.7% in the first quarter. Bank of Montreal Can now owns 3,323 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 1,118 shares during the last quarter. Finally, Cornerstone Advisors Inc. acquired a new stake in shares of Portola Pharmaceuticals in the first quarter valued at approximately $46,000.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Featured Article: What are trading strategies for the 52-week high/low?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.